tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Amedisys (AMED) and Sangamo Biosciences (SGMO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amedisys (AMEDResearch Report) and Sangamo Biosciences (SGMOResearch Report) with bullish sentiments.

Amedisys (AMED)

Barclays analyst Sarah James maintained a Buy rating on Amedisys on February 25 and set a price target of $181.00. The company’s shares closed last Friday at $159.90.

According to TipRanks.com, James is a 5-star analyst with an average return of 13.9% and a 72.5% success rate. James covers the Healthcare sector, focusing on stocks such as Surgery Partners, Universal Health, and Tenet Healthcare.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amedisys with a $192.00 average price target, which is a 28.8% upside from current levels. In a report issued on February 25, BMO Capital also upgraded the stock to Buy with a $190.00 price target.

See today’s best-performing stocks on TipRanks >>

Sangamo Biosciences (SGMO)

In a report issued on February 25, Gena Wang from Barclays maintained a Buy rating on Sangamo Biosciences, with a price target of $13.00. The company’s shares closed last Friday at $5.90, close to its 52-week low of $5.13.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 17.3% and a 48.3% success rate. Wang covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Sigilon Therapeutics, and PTC Therapeutics.

Currently, the analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $14.75, a 141.8% upside from current levels. In a report issued on February 24, RBC Capital also maintained a Buy rating on the stock with a $22.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AMED:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed